Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 2/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | MGLL | Q99685 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 7/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.36 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5116073 | 0.92 | CYP11B1 (0.43) | CYP11B2CYP11B1NR3C1PGRMGLL | |
| Hydrochloric Acid SCHEMBL5123727 | 0.91 | CYP11B1 (0.42) | CYP11B2CYP11B1NR3C1PGRMGLL | |
| SCHEMBL5110755 | 0.90 | CYP11B1 (0.41) | CYP11B2CYP11B1NR3C1PGRMGLL | |
| SCHEMBL5108601 | 0.87 | CYP11B1 (0.43) | CYP11B2CYP11B1NR3C1PGRMGLL | |
| SCHEMBL5115900 | 0.86 | CHRNB4 (0.42) | CYP11B2CYP11B1KDM1ACHRNB4CHRNA3 | |
| SCHEMBL5115363 | 0.85 | CYP11B1 (0.41) | CYP11B2CYP11B1NR3C1PGRMGLL | |
| SCHEMBL5123104 | 0.82 | CHRNB4 (0.52) | CYP11B2CYP11B1CHRNB4CHRNA3 | |
| SCHEMBL5123133 | 0.81 | CHRNB4 (0.39) | CHRNB4CHRNA3HTR2AHTR2CHTR2B | |
| SCHEMBL6836268 | 0.81 | NR1H2 (0.43) | CYP11B2CYP11B1CHRNB4CHRNA3HTR2A | |
| SCHEMBL5115818 | 0.79 | HDAC8 (0.44) | NR3C1PGRMGLLGRIN2BGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106603-A1 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | PFIZER INC | 2004-06-03 | — | — | US | claimed |
| US-7442694-B2 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | PFIZER INC (US) | 2008-10-28 | — | — | US | disclosed |
| US-20040106603-A1 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | PFIZER INC | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106603-A1 | Diazabicyclic compounds useful in the treatment of CNS and other disorders | DBH, CHRNA6, DDT | CYP11B2 403/4885CYP11B1 273/4885NR3C1 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.